A Phase II Study of Concurrent Intensity-Modulated Radiation Therapy (IMRT),
Paclitaxel, and Pazopanib/Placebo for the Treatment of Anaplastic Thyroid Cancer

Full Title

A Randomized Phase II Study of Concurrent Intensity Modulated Radiation Therapy (IMRT), Paclitaxel and Pazopanib (NSC 737754)/Placebo, for the Treatment of Anaplastic Thyroid Cancer (RTOG 0912)


Chemotherapy plus radiation therapy to the neck is the standard treatment for anaplastic thyroid cancer. The purpose of this study is to evaluate the safety and effectiveness of adding pazopanib to chemoradiation (radiation plus the drug paclitaxel) in patients with anaplastic thyroid cancer.

Pazopanib is a drug that has been approved to treat advanced kidney cancer; however, its use in anaplastic thyroid cancer is considered investigational. Pazopanib interferes with cell growth and reduces the growth of new blood vessels. It may delay the growth of tumor cells.

Paclitaxel is a chemotherapy drug that has been shown to have activity against anaplastic thyroid cancer. Pazopanib give alone has had antitumor effects on anaplastic cancer cells in the laboratory, and when used together with paclitaxel, it has enhanced antitumor activity against other cancer cells.

In this study, patients will be randomly assigned to receive paclitaxel and radiation with pazopanib or a placebo.


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have a confirmed diagnosis of anaplastic thyroid cancer that has not yet been treated with systemic chemotherapy.
  • Patients may not have had prior radiation therapy to the same region to be targeted in this study.
  • At least 4 weeks must have passed since prior treatment and entry into the study.
  • Patients must be age 18 or older

For more information about this study and to inquire about eligibility, please contact Dr. Eric Sherman at 646-888-4234.